29 Investor presentation First three months of 2022 Core capabilities and additional t new opportunities across therapy Therapy areas Diabetes care Obesity care CVD NASH RBD RED Other areas Proteins / Peptides Oligonucleotide Currently active Exploratory po Note: Currently active means Novo Nordisk is currently pursuing research projects, while exploratory potential indicates that the pl RBD: Rare blood disorders; RED: Rare endocrine disorders; CVD: Cardiovascular disease; NASH: Non-alcoholic steatohepatitis; RNA:
Download PDF file